Asahi Kasei Pharma gains Japanese rights to zoledronic acid for osteoporosis
This article was originally published in Scrip
Asahi Kasei Pharma has licensed from Novartis the exclusive rights to develop and market zoledronic acid in Japan for the treatment of osteoporosis.
You may also be interested in...
Novel antibody-drug conjugate receives approval in Japan for second-line breast cancer, providing another push to Japanese firm’s strategic plan to build up its oncology operations.
Collaboration with fundraising Tokyo-based venture builds mid-sized firm's interest in cell-based therapies in a highly supportive regulatory environment.
New long-term clinical data with Takeda’s dengue vaccine contender show a durable response against all four serotypes and support the dosing regimen in an ongoing pivotal study.